Upon reviewing repeated prostate cancer screenings, researchers observed the absence of suspicious MRI findings in over 86% of men who had prostate-specific antigen (PSA) levels of 3 ng/mL or higher ...

Omitting systematic biopsy in men with elevated prostate-specific antigen (PSA) levels and negative MRI results, and performing only targeted biopsy of MRI-positive lesions, eliminated more than half ...

High-resolution microultrasonography-guided biopsy was non-inferior to MRI fusion-guided biopsy for detecting clinically significant prostate cancer (detection rates, 47.1% and 42.6%, respectively), a ...

Prostate cancer is the second-leading cause of cancer deaths in American men. Further, non-Hispanic Blacks have a higher incidence of prostate cancer and are more likely to die from it than are ...

There are several strategies for the early detection of prostate cancer. The first step is often a blood test for prostate-specific antigen (PSA). If PSA levels exceed a certain threshold, the next ...

Data on the efficacy and safety of screening for prostate cancer with magnetic resonance imaging (MRI) are needed from studies of follow-up screening. In a population-based trial that started in 2015, ...

MRI of the prostate, combined with a blood test, can help determine if a prostate lesion is clinically significant cancer, new research suggests. A new meta-analysis by investigators from Brigham and ...

MARKHAM, Ontario--(BUSINESS WIRE)--Exact Imaging today announced results from its OPTIMUM clinical trial demonstrating the non-inferiority of its ExactVu™ micro-ultrasound platform to MRI ...

Microultrasonography for prostate biopsy detected clinically significant cancer at rates comparable to MRI-guided approaches. Detection rates for clinically insignificant cancers did not differ among ...

After a comprehensive two-year follow-up, researchers found that MRI-guided stereotactic body radiotherapy (SBRT) for prostate cancer significantly reduced long-term side effects and improved quality ...